ADHERENCE TO ORAL CHEMOTHERAPY TREATMENT

作者：Martinez Sandra Font****s; Baro Natalia Creus; Conde Maite Martin; Sala Josep Ribas; Pujol Marian March

来源：Atencion Farmaceutica, 2011, 13(1): 24-+.

• ADHERENCE
• PHARMACEUTICAL CARE
• CANCER
• COMPLIANCE
• PATIENT INFORMATION
• THYROSINE KINASE INHIBITOR
• ORAL CHEMOTHERAPY

Objective: To estimate the adherence to oral chemotherapies and promote pharmaceutical care.
Design: 13-month open-ended prospective study in ambulatory patients. Stages: i) Brochure creation, satisfaction survey and pharmaceutical care; ii) Recruiting; Evaluation of results.
Method: Brochure creation. Personalized patient care. Recording and analysis of dispensations and adherence during such period.
Results: The average adherence was 90.35 +/- 15.16%. Adherence for pa-tients younger than 35 years was 96.69 +/- 7.43%, between 36-64 years, 91.79 +/- 14.8% and in older than 65 years, 85.96 +/- 16.48%. By drug: imatinib: 93.62 +/- 11.44%; sorafenib: 89.34 +/- 17.22%; sunitinib: 67.73 +/- 14.24% and dasatinib: 88.74 +/- 15.93%. By indication: leukemia 93.80 +/- 12.22%; renal cell carcinoma: 71.13 +/- 18.43%; hepatocellular carcinoma: 89.69 +/- 18.52%; GIST: 89.12 +/- 11.58%, others: 91.39 +/- 10.35%.
Discussion: Although adherence is essential for ensuring the therapeutic success, few studies exist focused on oral chemotherapy, with results hard to compare among each other Adherence improvement requires a continuous, dynamic and multidisciplinary process.

• 出版日期2011-2